Similarly, a recent real-world study of 69 advanced PD-L1 unselected NSCLC patients showed that first-line A + I therapy resulted in an ORR of 59% (95% CI, 32.7–84.9) and a mPFS of 13.1 months (95% CI, 9.0–17.2) (Qiu et al., 2020). Here, CD274 is linked to non-small cell lung carcinoma.